CATH Classification
Level | CATH Code | Description |
---|---|---|
3 | Alpha Beta | |
3.40 | 3-Layer(aba) Sandwich | |
3.40.50 | Rossmann fold | |
3.40.50.2000 | Glycogen Phosphorylase B; |
Domain Context
CATH Clusters
Superfamily | Glycogen Phosphorylase B; |
Functional Family | Alpha-1,4 glucan phosphorylase |
Enzyme Information
2.4.1.1 |
Glycogen phosphorylase.
based on mapping to UniProt P06737
((1->4)-alpha-D-glucosyl)(n) + phosphate = ((1->4)-alpha-D-glucosyl)(n-1) + alpha-D-glucose 1-phosphate.
-!- This entry covers several enzymes from different sources that act in vivo on different forms of (1->4)-alpha-D-glucans. -!- Some of these enzymes catalyze the first step in the degradation of large branched glycan polymers - the phosphorolytic cleavage of alpha-1,4-glucosidic bonds from the non-reducing ends of linear poly(1->4)-alpha-D-glucosyl chains within the polymers. -!- The enzyme stops when it reaches the fourth residue away from an alpha-1,6 branching point, leaving a highly branched core known as a limit dextrin. -!- The description (accepted name) of the enzyme should be modified for each specific instance by substituting 'glycogen' with the name of the natural substrate, e.g. maltodextrin phosphorylase, starch phosphorylase, etc.
|
UniProtKB Entries (1)
P06737 |
PYGL_HUMAN
Homo sapiens
Glycogen phosphorylase, liver form
|
PDB Structure
PDB | 3DDS |
External Links | |
Method | X-RAY DIFFRACTION |
Organism | |
Primary Citation |
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
Bioorg.Med.Chem.Lett.
|